Piramal Pharma Secures Majority Stake in Yapan Bio

Piramal Pharma Limited has completed the acquisition of a controlling 74% stake in Yapan Bio Private Limited for ₹76 crore ($7.95M USD). Yapan Bio, based in Hyderabad, specializes in manufacturing services for vaccines and biologics. This acquisition elevates Yapan from an associate company to a subsidiary within Piramal Pharma Solutions (PPS), enhancing its integrated large molecule CDMO services.

Piramal initially invested in Yapan Bio in 2021, aiming to expand its capabilities in biologics development. The latest transaction aligns with PPL's strategic focus on broadening its presence in the biologics sector. Yapan Bio's expertise will now reinforce PPS's ADCelerate™, a platform for rapid Phase I ADC development.

PPL's acquisition marks a strategic move in its growth plan, integrating Yapan Bio's capabilities to meet global demand for complex biologics. CEO Peter DeYoung emphasized that this investment strengthens their global network and patient-centric approach, streamlining access to essential therapies.